Search Tufts Medicine

This is a clinical study that explores the effects of Tai Chi or Wellness Education on the gut bacteria of patients with Osteoarthritis. Our intervention is aimed at decreasing pain and improving quality of life for osteoarthritis patients.

To measure bacterial changes, participants stool samples will be collected and analyzed.These results will help determine mechanisms between bacteria, pain and behavioral pathways as well as progress future research to the potential disease-modifying role of mind-body approaches.

The purpose of this study is to compare the usual treatment approach (surgery followed by chemotherapy) to using chemotherapy followed by surgery and then more chemotherapy

The study uses artificial intelligence (a phone app) to aid surgeons in promptly identifying a surgical site infection following your surgery. If enrolled, you would be asked to upload multiple pictures of your surgical site for your surgeon to review.

A global phase 3, multicenter, randomized, trial, to Determine the Efficacy and Safety of Durvalumab in combination with Tremelimumab and Enfortumab Vedotin or Durvalumab in combination with Enfortumab vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or who refuse Cisplantin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer. The goal of the study is to explore the triplet combination of Durvalumab, Tremelimumab and Enfortumab Vedotin in terms of efficacy and safety compared to the current Standard Of Care (SOC).

The primary objective is to evaluate the efficacy of levosimendan TNX-103 compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance from Day 1 to Week 12. This is a multicenter, parallel, double-blind study in subjects with PH-HFpEF and will be screened for a 1:1 ratio to receive an oral dose of 2 mg/day levosimendan or placebo for Weeks 1 to 4 and 3 mg/day for Weeks 5 to 12.

This study will examine whether gum/periodontal diseases prior to cancer therapy impacts cancer therapy side-effects, quality of life, and response to treatment.

This is a phase 2 study that evaluates Lorundrostat in adults with Hypertension, Chronic Kidney Disease, and Albuminuria.

This is a study evaluating the safety and efficacy of bomedemstat (MK-3543) compared with the best available treatment (BAT) in participants with essential thrombocythemia (ET) who have an inadequate response to or are intolerant of hydroxyurea. The primary study hypothesis is that bomedemstat is superior to the best available treatment with respect to durable clinicohematologic response (DCHR).

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy).

This is a randomized, sham-controlled, subject-, assessor-, and Sponsor- masked trial to establish the safety and efficacy of bel-sar treatment via suprachoroidal (SC) administration in subjects with primary IL/CM. Bel-sar treatment incorporates administration of bel-sar drug product using a suprachoroidal space (SCS) microinjector and activation of bel-sar by a laser photoactivation device.

The proposed study compares Tai Chi + Routine Care with Routine Care alone to see if the addition of Tai Chi to Routine Care can improve Knee OA pain. The study will be conducted at Tufts Medical Center, UCLA, Boston Medical Center, and Cleveland Clinic. The study is funded by the National Institutes of Health National Center for Complementary and Integrative Health. We expect to enroll up to 480 subjects across all sites needed to complete the study

The purpose of this study is to learn if asundexian is safe for the participants, how it affects the body, and to look at how well it works to prevent future ischemic strokes in participants who already had had an acute non-cardioembolic ischemic stroke or high-risk TIA.

RGN-259 eye drops compared to placebo eye drops 5 times per day in both eyes for the treatment of Neurotrophic Keratopathy. Percentage of subjects achieving complete healing (defined as 0 mm lesion size) of the Persistent Epithelial Defect (PED) at Visit 5 (Day 29) determined by corneal fluorescein staining captured by corneal photography and analyzed by a central reading center

The study is being conducted to compare whether an optical correction of bifocal spectacle lenses (BFL) or single-vision spectacle lenses (SVL) is more effective for the treatment of children with esotropia greater at near. Children will be randomized to be treated with BFLs or SVLs for 3 years and be evaluated at regular intervals throughout the study to determine whether their condition has worsened.

Persistent corneal epithelial defect (PCED) is a persistent non-healing corneal defect or wound. KPI-012 is a novel, human bone-marrow derived human mesenchymal stem cell (hMSC) secretome composed of biologically active components, which have been shown in preclinical studies and early clinical trials to facilitate corneal healing. This study will investigate the efficacy and safety of KPI-012 eye drops 4 times daily for 8-weeks for healing of PCED.

Patients receiving maintenence hemodialysis will be screened for underlying cognitive impairment using the Montreal Cognitive Assessment (MoCA) Tool, a cognitive screening tool. Routine dialysis data, including biochemical measures and attendance records, will then be subsequently examined. Depending on the MoCA results, patients may be invited to participate in an interview to explore their experience with the MoCA screening tool and other aspects of their dialysis care.

This is a study to determine if a video that utilizes a peer to teach self administration of subcutaneous depot medroxyprogesterone is both effective and well accepted by adolescent patients who are already receiving ongoing treatment with depot medroxyprogesterone by a medical provider via an inter muscular injection.  Self administration can be done at home and therefore offers an alternative to traveling to a medical office.

This study is looking at home cooking patterns in people seen at the Tufts GI clinic with IBD and those without IBD. Participants will be given a questionnaire that will ask about different parts of the participants' home cooking patterns including attitudes, self-efficacy, and knowledge. By taking the responses to the questionnaire, we plan to examine different variables linked to home cooking pattern and how they differ between people seen at the GI clinic here at Tufts with IBD, and people seen at the clinic without IBD.

This is a randomized, phase 2, double-blind, placebo-controlled study of KER-012 in combination with background therapy in participants with PAH of World Health Organization (WHO) Group 1, functional class II-III. Participants will be randomly assigned in a 2:2:2:3 ratio to receive KER-012 (Dose A), KER-012 (Dose B), KER-012 (Dose C), or placebo by subcutaneous injection (SC) every 4 weeks for a period of 24 weeks in the placebo-controlled treatment period of the study while on background therapy.

The purpose of this study is to determine whether treatment with OP-1250 as a monotherapy will result in improvement of progression-free survival (PFS) and overall survival (OS) compared to SOC ET and assess the safety of treatment with OP-1250 in participants with ER+, HER2– advanced or MBC with and without estrogen receptor 1 gene (ESR1) activating mutation(-s) whose disease has relapsed or progressed on 1 or 2 prior lines of SOC ET, including a cyclin-dependent kinase (CDK) 4/6 inhibitor.